Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (SHE:301096) — Stock Price
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (SHE:301096) is currently trading at CN¥45.76 CNY, up 2.42% today. Over the past 52 weeks, shares have ranged between CN¥35.96 and CN¥68.99. This page tracks Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.'s live share price on the SHE exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see market value of Hangzhou Bio-Sincerity Pharma-Tech Co.Lt.
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (301096) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.'s daily closing share price and trading volume on the SHE exchange over the past year, giving a clear view of recent price momentum and liquidity.
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. Income Statement — Revenue, Profit & Earnings by Year
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.'s annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | CN¥677.99 Million | CN¥801.92 Million | CN¥1.02 Billion | CN¥607.41 Million | CN¥374.31 Million |
| Cost of Revenue | CN¥410.16 Million | CN¥385.06 Million | CN¥350.74 Million | CN¥198.18 Million | CN¥122.53 Million |
| Gross Profit | CN¥267.83 Million | CN¥416.86 Million | CN¥666.71 Million | CN¥409.23 Million | CN¥251.78 Million |
| Research & Development | CN¥189.87 Million | CN¥318.29 Million | CN¥241.02 Million | CN¥166.07 Million | CN¥81.14 Million |
| SG&A | CN¥26.83 Million | CN¥7.47 Million | CN¥79.77 Million | CN¥64.45 Million | CN¥24.37 Million |
| Total Operating Expenses | CN¥703.73 Million | CN¥785.52 Million | CN¥719.54 Million | CN¥446.57 Million | CN¥249.19 Million |
| Operating Income | CN¥-25.74 Million | CN¥16.40 Million | CN¥297.91 Million | CN¥160.84 Million | CN¥125.12 Million |
| EBITDA | — | — | — | CN¥256.72 Million | CN¥158.09 Million |
| EBIT | — | — | — | — | — |
| Interest Expense | CN¥21.02 Million | CN¥16.94 Million | CN¥7.00 Million | CN¥1.32 Million | CN¥3.67 Million |
| Income Before Tax | CN¥-91.14 Million | CN¥-36.06 Million | CN¥295.68 Million | CN¥190.91 Million | CN¥118.95 Million |
| Income Tax Expense | — | — | — | — | — |
| Net Income | CN¥-90.40 Million | CN¥-52.74 Million | CN¥271.97 Million | CN¥194.16 Million | CN¥111.09 Million |
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.'s financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | CN¥3.69 Billion | CN¥3.72 Billion | CN¥3.67 Billion | CN¥2.93 Billion | CN¥2.92 Billion |
| Total Current Assets | CN¥1.55 Billion | CN¥1.55 Billion | CN¥1.61 Billion | CN¥1.61 Billion | CN¥2.23 Billion |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | CN¥80.00 Million | CN¥83.00 Million | — | — | — |
| Net Receivables | CN¥467.21 Million | CN¥361.49 Million | CN¥199.92 Million | CN¥149.52 Million | CN¥76.76 Million |
| Inventory | CN¥176.44 Million | CN¥177.34 Million | CN¥93.17 Million | CN¥66.05 Million | CN¥22.85 Million |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | — | — | — | — | — |
| Total Liabilities | CN¥1.20 Billion | CN¥1.14 Billion | CN¥984.97 Million | CN¥447.45 Million | CN¥607.10 Million |
| Total Current Liabilities | CN¥919.91 Million | CN¥769.38 Million | CN¥846.19 Million | CN¥290.70 Million | CN¥472.69 Million |
| Long-term Debt | CN¥189.51 Million | CN¥244.00 Million | — | — | CN¥40.44 Million |
| Net Debt | CN¥407.52 Million | CN¥175.11 Million | — | — | — |
| Total Stockholder Equity | CN¥2.49 Billion | CN¥2.58 Billion | CN¥2.68 Billion | CN¥2.48 Billion | CN¥2.32 Billion |
| Retained Earnings | CN¥268.48 Million | CN¥358.88 Million | CN¥444.22 Million | CN¥270.47 Million | CN¥163.29 Million |
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | CN¥-154.64 Million | CN¥-195.86 Million | CN¥90.45 Million | CN¥259.41 Million | CN¥145.42 Million |
| Capital Expenditures | CN¥97.92 Million | CN¥395.10 Million | CN¥688.60 Million | CN¥591.58 Million | CN¥248.45 Million |
| Free Cash Flow | CN¥-252.56 Million | CN¥-590.96 Million | CN¥-598.15 Million | CN¥-332.16 Million | CN¥-103.02 Million |
| Investing Cash Flow | — | — | — | — | — |
| Financing Cash Flow | — | — | — | — | — |
| Dividends Paid | CN¥20.52 Million | CN¥48.77 Million | CN¥92.81 Million | CN¥66.55 Million | CN¥10.13 Million |
| Stock-Based Compensation | — | — | — | — | — |
| Depreciation | CN¥157.64 Million | CN¥145.80 Million | CN¥90.60 Million | CN¥64.49 Million | CN¥35.48 Million |
| Change in Cash | CN¥-135.68 Million | CN¥-362.29 Million | CN¥-432.62 Million | CN¥-797.93 Million | CN¥1.88 Billion |
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. Earnings History — EPS Actual vs. Analyst Estimates
Track Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.'s quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Mar 31, 2026 | 0.12 | — | — |
| Dec 31, 2025 | -0.89 | — | — |
| Sep 30, 2025 | 0.03 | — | — |
| Jun 30, 2025 | 0.27 | — | — |
| Apr 22, 2025 | -0.24 | — | — |
| Dec 31, 2024 | -1.79 | — | — |
| Oct 28, 2024 | 0.07 | — | — |
| Jun 30, 2024 | 0.78 | — | — |